Baseline interleukin‐10 levels as a predictive biomarker for achieving clinical response with abatacept in disease‐modifying antirheumatic drug‐naive and anticitrullinated protein antibody‐positive patients with early rheumatoid arthritis
Treatment with abatacept+MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept+MTX versus placebo+MTX across clinical outcomes. Findings suggest a well-suited mechanism of action for abatacept+MTX in patients with early RA and high baseline IL-10 levels.
Authors
- Ian M. Catlett (ORCID: https://orcid.org/0000-0001-6220-2626)
- Roy Fleischmann (ORCID: https://orcid.org/0000-0002-6630-1477)
- Y. Li
- S. Connolly
- C. Bingham
- Peter H Schafer (ORCID: https://orcid.org/0000-0002-3880-0850)
- Jinqi Liu
- Thomas W J Huizinga
- Yoshiya Tanaka
- Kai Fu
- Paul Emery
- Vivian P Bykerk
- Chun Wu
- Michael A Maldonado
- Robert Wong
Institutions
- Hospital for Special Surgery (US)
- Johns Hopkins University (US)
- PAREXEL International (United Kingdom) (GB)
- University of Occupational and Environmental Health Japan (JP)
- Johns Hopkins Medicine (US)
- Leiden University Medical Center (NL)
- Metroplex Clinical Research Center (US)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Bristol-Myers Squibb (Sweden) (SE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1002/art.70106
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00